Real-World Health Care Resource Utilization and Costs Among Patients with Activated Phosphoinositide 3-Kinase Delta (PI3Kδ) Syndrome in the United States
Higher HRU and health care costs among patients with APDS vs controls reflect the high clinical and economic burden of APDS.
Authors
- Ana Urosevic
- François Laliberté (ORCID: https://orcid.org/0000-0003-2601-6214)
- Malena Mahendran
- Guillaume Germain (ORCID: https://orcid.org/0000-0002-4525-7673)
- Nicholas L. Rider (ORCID: https://orcid.org/0000-0003-2549-0678)
- Amanda Harrington
Institutions
- Pharming Group (Netherlands) (NL)
- Group for Research in Decision Analysis (CA)
- Carilion Clinic (US)
- Virginia Tech (US)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2025-10-08
- DOI
- https://doi.org/10.1007/s12325-025-03377-3
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00